investigation and management of obesity
DESCRIPTION
INVESTIGATION AND MANAGEMENT OF OBESITY. Dr Ogunwale O.O. MBBS Lagos Snr Registrar EDM Div. LUTH. OUTLINE. INTRODUCTION CLASSIFICATION AIMS OF INVESTIGATION INVESTIGATIONS TREATMENT GUIDELINES NON-PHARMACOLOGICAL MGT PHARMACOLOGICAL MGT SURGICAL MGT BENEFITS OF WEIGHT LOSS - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: INVESTIGATION AND MANAGEMENT OF OBESITY](https://reader031.vdocument.in/reader031/viewer/2022013101/5681482b550346895db54f65/html5/thumbnails/1.jpg)
INVESTIGATION AND MANAGEMENT OF OBESITY
Dr Ogunwale O.O. MBBS LagosSnr Registrar EDM Div. LUTH
![Page 2: INVESTIGATION AND MANAGEMENT OF OBESITY](https://reader031.vdocument.in/reader031/viewer/2022013101/5681482b550346895db54f65/html5/thumbnails/2.jpg)
OUTLINE• INTRODUCTION• CLASSIFICATION• AIMS OF INVESTIGATION• INVESTIGATIONS• TREATMENT GUIDELINES • NON-PHARMACOLOGICAL MGT• PHARMACOLOGICAL MGT• SURGICAL MGT• BENEFITS OF WEIGHT LOSS• COMPLICATIONS OF TREATMENT• CONCLUSION• REFERENCES
![Page 3: INVESTIGATION AND MANAGEMENT OF OBESITY](https://reader031.vdocument.in/reader031/viewer/2022013101/5681482b550346895db54f65/html5/thumbnails/3.jpg)
INTRODUCTION
• Basically a clinical/anthropometric diagnosis• History & PE vital.• Underlying cause needs be investigated• Classification based on BMI • Also on Body Fat Distribution/%• Not necessarily about ↑weight. but ↑body
fat• Mgmt. is multidisciplinary
![Page 4: INVESTIGATION AND MANAGEMENT OF OBESITY](https://reader031.vdocument.in/reader031/viewer/2022013101/5681482b550346895db54f65/html5/thumbnails/4.jpg)
CLASSIFICATION
BMI (Kg/m2) Body Fat Percentage (%)Grade Male Female
Normal 15-20 25-30
Borderline 21-25 30-33
Obese >25 >33
Normal 18.5-24.9
Overweight 25-29.9
Grade1 Obese 30-34.9
Grade 2 35-39.9
Grade 3/Morbid ≥40
![Page 5: INVESTIGATION AND MANAGEMENT OF OBESITY](https://reader031.vdocument.in/reader031/viewer/2022013101/5681482b550346895db54f65/html5/thumbnails/5.jpg)
CLASSIFICATION
• Surgical : Super Obese BMI : ≥ 50• BF% : Calculated from Deurenberg’s Equation• 1.2(BMI)+0.23(Age)-10.8(Sex)-5.4• Sex : 1 for Male, 0 for Female• Both Underweight & Overweight are assoc.
with ↑risk of dx.• Risk ↑ with ↑ Obesity
![Page 6: INVESTIGATION AND MANAGEMENT OF OBESITY](https://reader031.vdocument.in/reader031/viewer/2022013101/5681482b550346895db54f65/html5/thumbnails/6.jpg)
AIMS OF INVESTIGATION
• Confirm diagnosis & r/o differentials• Find underlying aetiology• Complications & Comorbidities
![Page 7: INVESTIGATION AND MANAGEMENT OF OBESITY](https://reader031.vdocument.in/reader031/viewer/2022013101/5681482b550346895db54f65/html5/thumbnails/7.jpg)
INVESTIGATIONS
• BMI = Wt in Kg/ (Ht)2 in m 2
• Waist Circumference• Sagittal Abdominal Diameter• Caliper-derived measurements of skin-fold
thickness*• Bioelectrical impedance analysis**• Underwater weighing***
![Page 8: INVESTIGATION AND MANAGEMENT OF OBESITY](https://reader031.vdocument.in/reader031/viewer/2022013101/5681482b550346895db54f65/html5/thumbnails/8.jpg)
INVESTIGATIONS
![Page 9: INVESTIGATION AND MANAGEMENT OF OBESITY](https://reader031.vdocument.in/reader031/viewer/2022013101/5681482b550346895db54f65/html5/thumbnails/9.jpg)
INVESTIGATIONS
![Page 10: INVESTIGATION AND MANAGEMENT OF OBESITY](https://reader031.vdocument.in/reader031/viewer/2022013101/5681482b550346895db54f65/html5/thumbnails/10.jpg)
INVESTIGATIONS
![Page 11: INVESTIGATION AND MANAGEMENT OF OBESITY](https://reader031.vdocument.in/reader031/viewer/2022013101/5681482b550346895db54f65/html5/thumbnails/11.jpg)
INVESTIGATIONSWC Male (in cm) Female(in cm)
WHO 102 88
IDF 94 80
Asian 90 80
Japan & China 85 80
Nigeria (Okafor et al) 97 95
![Page 12: INVESTIGATION AND MANAGEMENT OF OBESITY](https://reader031.vdocument.in/reader031/viewer/2022013101/5681482b550346895db54f65/html5/thumbnails/12.jpg)
INVESTIGATIONHarpenden Professional Skinfold Caliper
![Page 13: INVESTIGATION AND MANAGEMENT OF OBESITY](https://reader031.vdocument.in/reader031/viewer/2022013101/5681482b550346895db54f65/html5/thumbnails/13.jpg)
INVESTIGATION
![Page 14: INVESTIGATION AND MANAGEMENT OF OBESITY](https://reader031.vdocument.in/reader031/viewer/2022013101/5681482b550346895db54f65/html5/thumbnails/14.jpg)
INVESTIGATION
• Ultrasonography Fat thickness• Abd USS : NAFLD, Gallstones , Ovarian Cysts• Dual-energy radiographic absorptiometry
(DEXA)• Abd CT Scan (at L4/L5)• Abd MRI
![Page 15: INVESTIGATION AND MANAGEMENT OF OBESITY](https://reader031.vdocument.in/reader031/viewer/2022013101/5681482b550346895db54f65/html5/thumbnails/15.jpg)
INVESTIGATIONs
• FLP• LFT• TFT• FBG• C-peptide and Insulin Studies• Brain MRI*• Genetic studies **• GH & IGF-1 Assays.
![Page 16: INVESTIGATION AND MANAGEMENT OF OBESITY](https://reader031.vdocument.in/reader031/viewer/2022013101/5681482b550346895db54f65/html5/thumbnails/16.jpg)
TREATMENT GUIDELINESBMI (kg/m2) Conventional
Therapy*Pharmacotherapy† Surgery‡
25.0-26.9 With CHD risk factors or obesity-related disease
No No
27.0-29.9 With CHD risk factors or obesity-related disease
With obesity-related disease
No
30.0-34.9 Yes Yes No
35.0-39.9 Yes Yes With obesity-related disease
≥40 Yes Yes Yes
![Page 17: INVESTIGATION AND MANAGEMENT OF OBESITY](https://reader031.vdocument.in/reader031/viewer/2022013101/5681482b550346895db54f65/html5/thumbnails/17.jpg)
NON-PHARMACOLOGICAL MGT
• Diet, Physical Activity & Behavioural Therapy• Self-monitoring of caloric intake & physical
activity• Goal setting*• Stimulus control• Non-food rewards• Relapse prevention
![Page 18: INVESTIGATION AND MANAGEMENT OF OBESITY](https://reader031.vdocument.in/reader031/viewer/2022013101/5681482b550346895db54f65/html5/thumbnails/18.jpg)
NON-PHARMACOLOGICAL MGT
• Goals should be SMART• Who - Who is involved?• What - What do I want to accomplish?• Where - Identify a location• When - Establish a time frame• Which - Identify requirements and constraints• Why - Identify specific reasons for or purpose
or benefits of the goal
![Page 19: INVESTIGATION AND MANAGEMENT OF OBESITY](https://reader031.vdocument.in/reader031/viewer/2022013101/5681482b550346895db54f65/html5/thumbnails/19.jpg)
NON-PHARMACOLOGICAL MGT
• Weight-loss programs• 3 major phases :• Pre-inclusion screening phase*• Weight-loss phase• Maintenance phase - Can last for rest of pt's
life but ideally lasts for at least 1 yr post program completion
![Page 20: INVESTIGATION AND MANAGEMENT OF OBESITY](https://reader031.vdocument.in/reader031/viewer/2022013101/5681482b550346895db54f65/html5/thumbnails/20.jpg)
NON-PHARMACOLOGICAL MGT
• DIET• Low Calorie Diet :800 - 1500 kcal/day • Very Low Calorie Diet < 800 kcal/day usu. high
in protein (70-100 g/day) & low in fat (<15 g/day).
• Usu. Taken As Liquid Formula, Nutritional Bars• Conventional Food : mostly lean meat, fish -
known as protein-sparing modified fasts.
![Page 21: INVESTIGATION AND MANAGEMENT OF OBESITY](https://reader031.vdocument.in/reader031/viewer/2022013101/5681482b550346895db54f65/html5/thumbnails/21.jpg)
NON-PHARMACOLOGICAL MGT
• Physical Activity• More of Aerobic Isotonic Exercise• Less of Anaerobic Isometric/ Resistance
Exercise
![Page 22: INVESTIGATION AND MANAGEMENT OF OBESITY](https://reader031.vdocument.in/reader031/viewer/2022013101/5681482b550346895db54f65/html5/thumbnails/22.jpg)
PHARMACOLOGICAL MGT
• Centrally acting medications that impair dietary intake (A)
• Medications that act peripherally to impair dietary absorption(B)
• Medications that increase energy expenditure (C)
![Page 23: INVESTIGATION AND MANAGEMENT OF OBESITY](https://reader031.vdocument.in/reader031/viewer/2022013101/5681482b550346895db54f65/html5/thumbnails/23.jpg)
PHARMACOLOGICAL MGT
• Lipase Inhibitors : Orlistat (B)• Sibutramine (C)• Lorcaserin (A)• Sympathomimetic Amines Phendimetrazine,
Phentermine ,Diethylpropion, Benzphetamine Mazindol (A)
• Antidiabetic agents
![Page 24: INVESTIGATION AND MANAGEMENT OF OBESITY](https://reader031.vdocument.in/reader031/viewer/2022013101/5681482b550346895db54f65/html5/thumbnails/24.jpg)
PHARMACOLOGICAL MGT
• Of the drugs the following are FDA-approved:• Lorcaserin (Belviq)• Phentermine/topiramate (Qsymia)• Orlistat (Xenical) • Sibutramine no longer approved
![Page 25: INVESTIGATION AND MANAGEMENT OF OBESITY](https://reader031.vdocument.in/reader031/viewer/2022013101/5681482b550346895db54f65/html5/thumbnails/25.jpg)
SURGICAL MGT
• BARIATIC SURGERY• Roux-en-Y gastric bypass (B)• Adjustable gastric banding (R)• Gastric sleeve surgery (R)• Vertical sleeve gastrectomy (R)• Horizontal (Silastic ring) gastroplasty (R)• Vertical banded gastroplasty (R)• Duodenal-switch procedures(B)• Biliopancreatic diversion (B)
![Page 26: INVESTIGATION AND MANAGEMENT OF OBESITY](https://reader031.vdocument.in/reader031/viewer/2022013101/5681482b550346895db54f65/html5/thumbnails/26.jpg)
SURGICAL MGT
![Page 27: INVESTIGATION AND MANAGEMENT OF OBESITY](https://reader031.vdocument.in/reader031/viewer/2022013101/5681482b550346895db54f65/html5/thumbnails/27.jpg)
SURGICAL MGT
![Page 28: INVESTIGATION AND MANAGEMENT OF OBESITY](https://reader031.vdocument.in/reader031/viewer/2022013101/5681482b550346895db54f65/html5/thumbnails/28.jpg)
SURGICAL MGT
• Vertical banded gastroplasty
![Page 29: INVESTIGATION AND MANAGEMENT OF OBESITY](https://reader031.vdocument.in/reader031/viewer/2022013101/5681482b550346895db54f65/html5/thumbnails/29.jpg)
SURGICAL MGT
![Page 30: INVESTIGATION AND MANAGEMENT OF OBESITY](https://reader031.vdocument.in/reader031/viewer/2022013101/5681482b550346895db54f65/html5/thumbnails/30.jpg)
SURGICAL MGT
• Morbid Obesity• When Conventional Rx & Drug Rx Fail• Benefits : Improved Obstructive sleep apnea• Type 2 DM, Hypertension, CCF, Asthma,
Dyslipidaemia• Peripheral oedema, Respiratory insufficiency• Esophagitis, Pseudotumor cerebri, OA, VTE• Operative risk• Urinary incontinence
![Page 31: INVESTIGATION AND MANAGEMENT OF OBESITY](https://reader031.vdocument.in/reader031/viewer/2022013101/5681482b550346895db54f65/html5/thumbnails/31.jpg)
BENEFITS
• Improved Glycaemic Control• BP Control• Dyslipidaemia Control• ↓ CV Risk• Improved Pulm. Fx• Improved Reproductive & Urinary Fx
![Page 32: INVESTIGATION AND MANAGEMENT OF OBESITY](https://reader031.vdocument.in/reader031/viewer/2022013101/5681482b550346895db54f65/html5/thumbnails/32.jpg)
COMPLICATIONS OF Rx
• Electrolyte Disturbances : Ketosis, ↓K+
• Arrhythmias• Malabsorption• Malnutrition• Hyperuricaemia• Cholithiasis• Depression & Eating Disorders
![Page 33: INVESTIGATION AND MANAGEMENT OF OBESITY](https://reader031.vdocument.in/reader031/viewer/2022013101/5681482b550346895db54f65/html5/thumbnails/33.jpg)
CONCLUSION
• Obesity is basically a clinical diagnosis• More about body fat than weight• Hx & PE very important to evaluate co-
morbidities and Cx• Management primarily non-pharmacological• Multidisciplinary• Benefits of Rx include ↓CV Risk, ↑Pulm. Fx
and regression of co-morbidities
![Page 34: INVESTIGATION AND MANAGEMENT OF OBESITY](https://reader031.vdocument.in/reader031/viewer/2022013101/5681482b550346895db54f65/html5/thumbnails/34.jpg)
REFERENCES• Klein S, Fabbrini E, Romijnin JA Obesity in Melmed S, Polonsky KS,
Larsen PR, Kronenberg HM (eds.), Williams Textbook of Endocrinology, 12th ed. Saunders, 2011. ch 36 pp 1605- 1625
• Hamdy O, Citkowitz E, Uwaifo GI, Oral EA Obesity http://emedicine.medscape.com/article/123702. Updated : Nov 25, 2013
• de Souza NC, de Oliveira EP Sagittal abdominal diameter shows better correlation with cardiovascular risk factors than waist circumference and BMI Journal of Diabetes & Metabolic Disorders 2013 12:41
• http://www.topendsports.com/testing/skinfold-sites.htm Accessed Dec 4,2013
• http://www.ebay.com/itm/Harpenden-Professional-Skinfold-Caliper-/320795435670 Accessed Dec 4, 2013
![Page 35: INVESTIGATION AND MANAGEMENT OF OBESITY](https://reader031.vdocument.in/reader031/viewer/2022013101/5681482b550346895db54f65/html5/thumbnails/35.jpg)
REFERENCES• http://www.fitnessgram.net/protocols/skinfolds.pdf Accessed Dec 6 ,2013• Sagittal Diameter http://www.myhealthywaist.org/evaluating-cmr/clinical-
tools/sagittal-diameter/page/2/print.html. Accessed Dec 6, 2013• http://www.topendsports.com/testing/tests/underwater.htm Accessed Dec.
5,2013• http://www.topendsports.com/testing/siri-equation.htm Accessed Dec. 5,
2013• http://www.myhealthywaist.org/evaluating-cmr/clinical-tools/sagittal-
diameter/page/2/print.html Accessed Dec. 6,2013• WHO Technical Report Series. Diet, nutrition and the prevention of chronic
diseases http://whqlibdoc.who.int/trs/WHO_TRS_916.pdf Accessed Dec. 6, 2013
• http://www.nlm.nih.gov/medlineplus/ency/article/007199.htm. Updated 6/4/2012
![Page 36: INVESTIGATION AND MANAGEMENT OF OBESITY](https://reader031.vdocument.in/reader031/viewer/2022013101/5681482b550346895db54f65/html5/thumbnails/36.jpg)
THANK YOU